Toyobo to co-promote Catalent GPEx technology in Japan

GPEx technology is used to develop mammalian cell line and create stable, high expression cell lines that will speed biologics drug development.

TBI is a biologics supplier and contract provider of large scale clinical and commercial bioreactors in Japan.

TBI owns and operates a GMP manufacturing plant with bioreactors ranging from 100L up to 4,000L located in Shiga, Japan.

Catalent Development Services business vice president and GMKent Payne said together, Catalent and Toyobo can now offer an advanced cell line development solution for customers in the Japanese market, from gene expression through commercialization of product.